Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ampio Pharmaceuticals Inc AMPE

Healthcare
Ampio Pharmaceuticals, Inc. is a drug discovery and development company. The Company is focused on combining scientific, clinical, and manufacturing capabilities to develop therapies aimed at treating conditions for which limited treatment options exist.

Recent & Breaking News (OTCPK:AMPE)

Ampio Deadline Alert

Newsfile October 10, 2022

ROSEN, Global Investor Counsel, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMPE

Newsfile October 9, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ampio Pharmaceuticals, Inc. - AMPE

Newsfile October 8, 2022

ROSEN, LEADING INVESTOR COUNSEL, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMPE

PR Newswire October 7, 2022

AMPE SHAREHOLDER ALERT: Jakubowitz Law Reminds Ampio Shareholders of a Lead Plaintiff Deadline of October 17, 2022

PR Newswire October 7, 2022

Ampio Deadline Alert

Newsfile October 6, 2022

DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 17, 2022 in Ampio Lawsuit - AMPE

Newsfile October 6, 2022

AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit

PR Newswire October 6, 2022

AMPE LAWSUIT ALERT: Levi & Korsinsky Notifies Ampio Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

PR Newswire October 6, 2022

Ampio Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 17, 2022 to Discuss Your Rights - AMPE

Newsfile October 4, 2022

Ampio Pharmaceuticals Issues Letter to Stockholders

PR Newswire October 4, 2022

Ampio Pharmaceuticals Announces NYSE American Has Commenced Delisting Proceedings

PR Newswire October 4, 2022

AMPE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 17, 2022 in the Class Action Filed on Behalf of Ampio Pharmaceuticals, Inc. Shareholders

PR Newswire October 4, 2022

Ampio Deadline Alert

Newsfile October 3, 2022

Ampio Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 17, 2022 to Discuss Your Rights - AMPE

Newsfile October 3, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ampio Pharmaceuticals, Inc. - AMPE

PR Newswire October 3, 2022

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Ampio Investors of a Lead Plaintiff Deadline of October 17, 2022

PR Newswire October 3, 2022

Ampio Deadline Alert

Newsfile October 2, 2022

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMPE

Newsfile October 1, 2022

Ampio Deadline Alert

Newsfile September 30, 2022